Stem Cell Therapy for Rheumatoid Arthritis: What the Research Shows and Who May Be a Candidate

An honest guide to mesenchymal stem cell (MSC) infusions for rheumatoid arthritis: what the trials found, how long effects lasted, our 300M IV protocol, the $11,500 price, risks and who may be a candidate.
Older adult's hands holding a warm mug by a sunny window

If you live with rheumatoid arthritis (RA), you know the routine: the morning stiffness, the swollen knuckles, the lab work, the dose changes. Maybe methotrexate helped for a while, or you’ve cycled through a biologic or two, and you’ve started wondering whether anything else is out there.

Mesenchymal stem cell (MSC) infusions are one of the things people find. This guide explains, as plainly as we can, what RA is doing in your body, what the published trials of MSCs show and don’t show, exactly what our protocol involves and costs, and who may be a reasonable candidate. MSC therapy for RA is investigational. Some people in studies improved, some didn’t, the effects have tended to fade, and nobody can promise you a result.

What Is Happening in RA, and Why It's Hard to Treat

RA is an autoimmune disease. The immune system attacks the lining of the joints (the synovium), causing pain, swelling and stiffness, and over time it can erode cartilage and bone.

Today’s standard care is effective for many people. The 2021 American College of Rheumatology guideline recommends starting with methotrexate, adding a biologic or JAK inhibitor when needed, and checking disease activity regularly, with a first goal of low disease activity. The guideline itself notes that full remission may not be achievable for many patients. That gap is why some people look beyond their current medications.

One thing to say clearly up front: MSC therapy is not part of any RA treatment guideline, and the guideline covers only drugs approved by the U.S. FDA for RA. Nothing in this article suggests MSCs should replace your rheumatologist or your medication.

How MSCs Are Thought to Work

Mesenchymal stem cells are best understood as signaling cells. Most of what they appear to do happens through paracrine signaling: they release proteins and other molecules that influence nearby immune cells. They can turn into cartilage or bone cells in a lab dish, but there’s little evidence that infused cells settle in your joints and rebuild them.

In RA, the idea is immunomodulation. Early work suggests MSCs may lower inflammatory signals such as TNF-alpha and interleukin-6 and increase regulatory T cells, which help keep the immune response in check. That is a biological rationale, not proof of benefit.

What Do the Trials Show?

The honest summary is this: the studies are small and varied, mostly show short-term improvements in disease activity scores, and haven’t established lasting control. Here are the main ones.

  • A 172-patient study of umbilical cord MSCs in China (Wang et al., 2013). People with active RA who weren’t responding well to medication kept taking their DMARDs and received either cord MSCs (40 million cells per infusion, by IV) or a control infusion without cells. The cell group improved on standard RA measures (ACR improvement criteria, DAS28, HAQ), and TNF-alpha and IL-6 fell. The benefit lasted about 3 to 6 months without more infusions, and repeat infusions seemed to help again. No serious infusion-related problems were reported, though about 4% of the cell group had brief chills or fever. This is the study most similar to our cells, but its design is described as an ongoing cohort, not a fully blinded trial.
  • A 63-patient study adding interferon-gamma (He et al., 2020). Everyone received cord MSCs; half also received interferon-gamma. At three months, 53% of the MSC-only group had an ACR20 response (at least 20% improvement) compared with 93% of the combination group. There was no placebo group, so it shows what happened after MSCs, not what MSCs caused.
  • A placebo-controlled trial of donor fat-derived MSCs (Álvaro-Gracia et al., 2017). Fifty-three people whose RA had failed at least two biologics received three IV infusions of 1, 2 or 4 million cells per kilogram, or placebo. The treatment was generally tolerated, but there was no clear dose effect, and the benefit was small and short-lived: ACR20 responses at three months were 15% to 25% in the cell groups versus 0% in the seven placebo patients. One patient had a small stroke (a lacunar infarction) judged possibly related to treatment. The authors described “a trend” toward benefit, not a proven one.
  • A small cord-blood MSC safety trial (Park et al., 2018). Nine people on methotrexate received one IV infusion of up to 100 million cord blood MSCs. There were no serious adverse events and disease scores improved over four weeks, but there was no comparison group.
  • Pooled reviews. A 2023 meta-analysis of three randomized trials and one non-randomized trial (358 patients) found lower DAS28 and HAQ scores and no clear difference in adverse events, but the estimates were imprecise and the improvement wasn’t seen beyond 12 months without further treatment. A 2023 analysis of 7 randomized and 12 non-randomized trials (682 people, including some stem cell transplant studies) also found DAS28 improvements, with moderate risk of bias and high variability between studies.

What this means in practice: a few hundred patients have been studied, mostly while staying on their regular medication. Improvements in disease activity were reported, usually for months rather than years, and large, long, well-controlled trials haven’t been done. We can’t tell you that MSCs control RA, and we won’t call it a cure or say it “reprograms” your immune system.

What MSC Therapy Can and Can't Do

  • It is not shown to replace methotrexate, biologics or other RA medication. In most trials, patients stayed on them.
  • It is not shown to rebuild eroded cartilage or bone.
  • It may reduce inflammation and symptoms for a period of months in some people. Some people notice little or no change.
  • Because effects in the trials faded after about 3 to 6 months, ask any clinic what its plan is for repeat treatment.

Our RA Protocol

Here’s what our rheumatoid arthritis treatment includes:

IV infusion 300 million culture-expanded MSCs
Also included An NAD+ and high-dose vitamin C IV drip after the stem cells, and a full blood panel
Cells Donor MSCs from Wharton’s jelly (umbilical cord tissue) and placenta from healthy, live births
Price $11,500 USD
Minimum stay 4 days in Bucerías, near Puerto Vallarta

A note on dose, because we think you should know it: the published RA trials used a range of cell numbers, from about 40 million per infusion up to about 4 million per kilogram of body weight, and no trial showed that a higher dose worked better. Our 300 million dose is roughly 4 million cells per kilogram for a 154 lb (70 kg) adult, near the top of that range. We offer it as a single treatment, whereas several trials used repeat infusions. Our physician will explain the reasoning for your case.

Our cells are grown in our own lab in Bucerías, which holds three COFEPRIS licenses (Mexico’s federal health regulator) covering stem cell production, cryobank storage and regenerative medicine practice. Cells are expanded in a GMP-grade, xeno-free medium in a cleanroom, tested by COFEPRIS-authorized third-party labs for identity (flow cytometry), mycoplasma and endotoxins, and given within 24 hours of leaving culture. You can see the licenses on our certified stem cells page, and our article on how our cells are made and tested explains more.

COFEPRIS licenses our facility and lab. That isn’t the same as approving MSC therapy for RA, and these treatments are not FDA-approved in the United States.

Risks and Side Effects

We’d rather you hear about risks from us before you book. Based on our experience with this protocol:

  • Fever or headache for a few hours after the IV, or the next day, in about 1 in 100 patients. Chills, flu-like feelings and nausea were also the most commonly reported effects in published trials.
  • Infection is a risk with any IV. People with RA often take medicines that dampen the immune system, so we review your infection history and screening results before treatment.
  • Clots or vein irritation are a rare risk with any IV, which is one reason we do bloodwork first.
  • Immune reactions to donor cells. In the fat-derived MSC trial above, about 1 in 5 patients developed antibodies against the donor cells. What that means over the long term isn’t known.
  • A flare or no response. Some patients notice no change, and some notice symptoms returning after a few months.

Long-term safety data for donor MSCs in RA are limited. The U.S. FDA has warned consumers about unapproved stem cell products and reported serious harms from some of them elsewhere. That’s part of why we publish our protocol, licenses and testing, and why a physician reviews every case before booking. Please don’t stop or change any RA medication, including methotrexate, biologics, JAK inhibitors or steroids, without talking to your own rheumatologist.

Who May Be a Candidate?

A physician reviews every case before you book anything. In general, people who may be reasonable candidates:

  • Have a confirmed RA diagnosis from a rheumatologist, with recent records and blood work
  • Still have active symptoms despite standard treatment, or can’t tolerate it
  • Understand the treatment is investigational and may not help
  • Are willing to keep their rheumatologist involved and not change their medication without them
  • Are well enough to travel and have no active infection

You may not be a good candidate if:

  • You’ve had cancer in the past five years (we don’t treat these patients)
  • You have an active infection, or screening suggests one
  • Your main problem is a joint that is already badly damaged, where surgery or a targeted joint treatment may matter more. Ask us about this in the consultation, because an IV infusion is aimed at immune activity, not at rebuilding a worn joint.

If we don’t think treatment is likely to be worthwhile for you, we’ll tell you.

Your 4-Day Trip

Day What happens
Day 1 Arrive in Puerto Vallarta and rest
Day 2 Bloodwork, then payment
Day 3 Treatment: the IV infusion followed by the NAD+ and vitamin C drip
Day 4 Fly home

Exact days can shift with scheduling, and you’re welcome to stay longer. If fatigue or stiffness makes travel harder, tell us early so we can plan transport and rest time. Our travel guide and hotel options can help you plan.

After Treatment

We follow up remotely at 3, 6 and 12 months. In the trials, any benefit tended to appear over the first weeks to months and then fade, so we encourage you to keep seeing your rheumatologist and to track the same measures they use, such as swollen and tender joint counts, CRP and ESR blood tests, and your own function. That’s the best way to know whether the treatment did anything for you. If you notice no change by six months, tell us honestly so we can talk through what that means.

Seek medical care right away if you develop a fever that doesn’t settle, chest pain, sudden weakness, trouble speaking or severe shortness of breath after any infusion.

Questions to Ask Any Clinic

Whether you choose us or someone else, ask:

  1. What cell type and dose will I get, and what published trial supports that exact product?
  2. Are the cells tested before use, and by whom?
  3. What happens to my current RA medication, and who decides?
  4. How will we measure whether it worked, and what is the plan if the benefit fades?
  5. What does the price include, and what’s extra?

Our guides on how to choose a stem cell clinic and allogeneic vs autologous cells go deeper.

Frequently Asked Questions

Is stem cell therapy a cure for rheumatoid arthritis? No. MSC therapy is investigational. Some patients report less pain, swelling and stiffness for a period, but RA can still flare, and no treatment we offer is a cure.

Can I stop my RA medication after treatment? Don’t stop or change any RA medication without your rheumatologist. In the trials, patients generally stayed on their usual drugs. Any medication change should be gradual and decided with your own doctor.

Can stem cells repair joint damage from RA? Trials haven’t shown that. MSCs appear to act mainly by calming inflammation through signals, not by rebuilding eroded cartilage or bone.

How long do results last? In published studies, benefits usually lasted about 3 to 6 months, and some wore off by 12 months without repeat treatment. Individual results vary. We follow up at 3, 6 and 12 months so you can see how you’re doing.

Why donor cells instead of my own? Our cells come from healthy donors, and we use them because they’re prepared and tested in our lab ahead of time. Some clinicians prefer donor cells for autoimmune disease, but the evidence is limited and reviews don’t all agree. Our article on allogeneic vs autologous cells explains the trade-offs.

How much does it cost? Our RA protocol is $11,500 USD, including the 300 million MSC IV, the NAD+ and vitamin C drip, and a full blood panel. Flights and hotel are separate. Insurance generally doesn’t cover it.

Thinking About Your Options?

If you’re wondering whether MSC therapy makes sense alongside your RA care, a free consultation is a good place to start. It’s a conversation, not a commitment. A physician will review your records, explain what the evidence does and doesn’t show for your situation, and tell you honestly whether we think treatment is a reasonable option.

Schedule your free consultation, call (888) 704-3977, WhatsApp +52 322 232 1055, or email info@dreambodyclinic.net.


Disclaimer: This article is for educational purposes and is not medical advice. Mesenchymal stem cell therapy for rheumatoid arthritis is investigational and is not approved by the U.S. FDA. Published evidence is limited, results vary, and some patients see little or no benefit. Treatment is provided in Mexico at a COFEPRIS-licensed facility. Do not stop or change any rheumatoid arthritis medication without your own doctor. Please consult your physician before making treatment decisions.

Share this post
Facebook
Twitter
LinkedIn
WhatsApp

More from the category

Featured articles

From our book shop